Cirrus Pharmaceuticals, a Kemwell company, which provides pharmaceutical contract development and manufacturing services, is investing in a flexible cGMP suite in its facility in Research Triangle Park, North Carolina.

“With this investment, we are bringing our customers a new service from our US facility,” said Ninad Deshpanday, president of R&D at Kemwell, in a company release. “We will offer our clients cGMP manufacturing services  for many dosage forms, including inhalation, liquids, topicals, and oral solids.”

The company has completed the design phase and expects the suite to be ready for service by April 2015.

Kemwell's R&D division employs over 175 scientists worldwide and provides services ranging from formulation development, analytical development and validation, to clinical trial manufacturing.​ Kemwell, with operations in the US, Sweden, and India, offers contract services from preformulation development to commercial-scale manufacturing for sterile and non-sterile forms with expertise in inhaled, nasal, oral, parenteral, and topical dosage forms. Kemwell acquired Cirrus Pharmaceuticals in 2013.